Market Cap
$2.9B
NAMS
NewAmsterdam Pharma Co N.V.
$23.20 ▼ -3.97%
Prev close $24.16Market cap$2.9B
ConsensusStrong Buy
12-mo target$50.34 (+117.0%)
▲ Bullish
Analyst conviction 9/10
Insider Selling Cluster (2 insiders)High Impact Filing (7/10) Biotech & Drug Discovery
Snapshot
The big-picture read on NAMS right now — valuation, ownership and activity at a glance.
Cap Size
Mid Cap
Analyst Consensus
Strong Buy (91%)
Insider Activity
$226.5K buy / $46.2M sell
Insider Net $
-$46.0M
SEC Reports
4
Price chart 30d -10.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.
Sep 30, 2026 Insider
Kastelein Johannes Jacob Pieter sold 50,246 shares
Chief Scientific Officer @ $25.03 ($1.3M)
Sep 30, 2026 Insider
Sep 16, 2026 SEC Kastelein Johannes Jacob Pieter acquired via exercise 50,246 shares
Chief Scientific Officer
CEO Michael Davidson purchased $227K of NAMS stock on the open market at $22.65/share, a standalone conviction buy. This
INSIDER-BUY — Impact 5/10
Sep 14, 2026 Insider
Aug 5, 2026 SEC Davidson Michael H. bought 10,000 shares
Chief Executive Officer @ $22.65 ($226.5K)
NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a positive opinion rec
8-K — Impact 7/10
NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending marketing authorization fo
8-K — Impact 7/10
Analyst ratings buy % +1.1%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
91% rate it Buy or better · 23 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 8, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 6, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
| Jun 30, 2026 | RBC Capital | MAINTAIN | Outperform | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 9 | 12 | 2 | 0 | 0 | 91% | |
| Aug 1, 2026 | 9 | 12 | 2 | 0 | 0 | 91% | |
| Jul 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Jun 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| May 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Apr 1, 2026 | 9 | 11 | 2 | 0 | 0 | 91% | |
| Mar 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% | |
| Feb 1, 2026 | 9 | 10 | 2 | 0 | 0 | 90% |
Price targets
Where 15 covering analysts think NAMS trades over the next 12 months.
$50.34 +117.0% upside Strong Buy
Current$23.20 Low$37.05 Median$50.44 High$59.61 15 analysts
$37.05$59.61
Analyst rating Strong Buy· 1.3/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
4 SEC filing reports analyzed · 3 bullish, 0 bearish, 0 mixed, 1 neutral · avg impact 6.0/10.
BULLISHINSIDER-BUY5/10
CEO Michael Davidson purchased $227K of NAMS stock on the open market at $22.65/share, a standalone
Sep 16, 2026
BULLISH8-K7/10
NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a
Aug 5, 2026
BULLISH8-K7/10
NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending market
Jul 24, 2026
NEUTRALPRESS-RELEASE5/10
{ "summary": "NewAmsterdam Pharma issued a press release announcing participation in an upcoming i
Apr 8, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAARDEN, The Netherlands and MIAMI, Oct. 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company
Oct 1, 2026
short_volume
Short Volume: NAMS — 55.2% short (0.4M / 0.7M)
Short: 389,660 | Exempt: 0 | TRF Vol: 706,115 | Short Ratio: 55.2% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
short_volume
Short Volume: NAMS — 60.2% short (0.5M / 0.8M)
Short: 456,135 | Exempt: 0 | TRF Vol: 757,626 | Short Ratio: 60.2% | Off-exchange volume (dark pool + OTC)
Sep 21, 2026
other
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
- First-in-Class approval supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM trials demonstrating significant LDL-C reductions with favorable tolerab
Sep 18, 2026
short_volume
Short Volume: NAMS — 61.2% short (0.6M / 0.9M)
Short: 560,491 | Exempt: 0 | TRF Vol: 915,589 | Short Ratio: 61.2% | Off-exchange volume (dark pool + OTC)
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.43 | $-0.54–$-0.29 | 18.4% | +2.6% | 0↑ 7↓ | $0.0B | 13 |
| Next Q | $-0.39 | $-0.55–$-0.23 | 26.3% | +1.1% | 3↑ 3↓ | $0.0B | 13 |
| Current FY | $-1.65 | $-1.87–$-1.43 | -13.5% | +0.2% | 1↑ 7↓ | $0.0B | 12 |
| Next FY | $-1.55 | $-2.74–$1.88 | 5.8% | -0.8% | 2↑ 4↓ | $0.1B | 12 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.434 | — |
| 7d ago | $-0.445 | +0.011 |
| 30d ago | $-0.446 | +0.012 |
| 60d ago | $-0.422 | -0.012 |
| 90d ago | $-0.420 | -0.014 |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
6 insiders, 43 transactions. Net -$46.0M — $226.5K bought, $46.2M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 30, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | SELL | 50,246 | $25.03 | $1.3M |
| Sep 30, 2026 | Kastelein Johannes Jacob Pieter | Chief Scientific Officer | EXERCISE | 50,246 | — | — |
| Sep 14, 2026 | Davidson Michael H. | Chief Executive Officer | BUY | 10,000 | $22.65 | $226.5K |
| Sep 4, 2026 | Smither John W | Director | SELL | 1,600 | $25.32 | $40.5K |
| Sep 1, 2026 | Gunning Robert William | Vice President, Controller | AWARD | 14,000 | — | — |
| Sep 1, 2026 | Gunning Robert William | Vice President, Controller | AWARD | 3,200 | — | — |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | EXERCISE | 80,000 | $11.17 | $893.6K |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | EXERCISE | 25,000 | $11.90 | $297.5K |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | SELL | 31,885 | $31.05 | $990.0K |
| Jul 20, 2026 | Kooij Louise Frederika | Chief Accounting Officer | SELL | 70,200 | $29.96 | $2.1M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for NAMS.
Shares short
15,660,444
Settlement Sep 15, 2026
Change vs prior
+16.9%
Semi-monthly cycle
Days to cover
9.9
At avg daily volume
Of shares outstanding
≈13.1%
Estimate — not % of float
All NAMS filing & press-release reports (4)
- INSIDER-BUY reportSep 16, 2026
- 8-K reportAug 5, 2026
- 8-K reportJul 24, 2026
- PRESS-RELEASE reportApr 8, 2026